Incorporation of targeted therapies such as inhibitors of epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) signaling have improved outcomes in human lung adenocarcinoma harboring sensitizing mutations (19, 20). The gene discussed is EGFR; the disease is lung adenocarcinoma.